Percentage of female patients aged 18 and over with HER2/neu positive invasive breast cancer who are administered trastuzumab
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.20 Testing Data Sources
-
1.14 Numerator
Patients for whom trastuzumab is administered within 12 months of diagnosis
-
1.15 Denominator
Female patients aged 18 and over with AJCC stage I (T1c) – III, HER2/neu positive breast cancer who receive chemotherapy
-
Exclusions
Denominator Exclusions:
o Patient transfer to practice after initiation of chemotherapy
Denominator Exceptions:
o Reason for not administering trastuzumab documented (e.g. patient declined, patient died, patient transferred, contraindication or other clinical exclusion, neoadjuvant chemotherapy or radiation therapy not complete)
-
OLD 1.12 MAT output not attachedAttached
-
Most Recent Endorsement ActivityEndorsed Cancer Fall Cycle 2019Initial EndorsementLast Updated
-
Steward Organization EmailSteward Organization Copyright
The Measure is not clinical guidelines, does not establish a standard of medical care, and has not been tested for all potential applications.
The Measure, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g., use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measure into a product or service that is sold, licensed or distributed for commercial gain.
Commercial uses of the Measure require a license agreement between the user and the American Society of Clinical Oncology (ASCO) and American Medical Association (AMA), [on behalf of the Physician Consortium for Performance Improvement® (PCPI®)] and prior written approval of ASCO, AMA, or PCPI. Neither ASCO, AMA, or PCPI, nor its members shall be responsible for any use of the Measures.
The AMA’s and PCPI’s significant past efforts and contributions to the development and updating of the Measure is acknowledged. ASCO is solely responsible for the review and enhancement (“Maintenance”) of the Measures as of January 2015.
ASCO encourages use of the Measures by other health care professionals, where appropriate.
THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND.
© 2020 American Medical Association and American Society of Clinical Oncology. All Rights Reserved.
Limited proprietary coding is contained in the Measure specification for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. ASCO, AMA, , PCPI and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specification.
CPT® contained in the Measures specifications is copyright 2004-2019 American Medical Association. LOINC® copyright 2004-2018 Regenstrief Institute, Inc. SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2018 College of American Pathologists. All Rights Reserved.
-
-
-
Risk AdjustmentRisk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
-
-
-
6.1.2 Current or Planned Use(s)
-